Ferrer takes novel antifungal into Phase III
This article was originally published in Scrip
Executive Summary
The private Spanish pharmaceutical company Ferrer is to begin a Phase III study early next year for what it hopes will be a best–in-class topical azole antifungal, arasertaconazole, for vulvovaginal candidiasis (VVC). The fast-acting broad-spectrum antifungal product showed rapid symptom relief and significant clinical and mycological benefits when given as a single vaginal suppository in a multicentre Phase II trial, the company said.